Rosenberry Patricia M, Niederhaus Silke V, Schweitzer Eugene J, Leeser David B
1 University of Maryland Shore Regional Health, Easton, MD, USA.
2 University of Maryland, Baltimore, Baltimore, MD, USA.
J Vasc Access. 2018 Nov;19(6):569-572. doi: 10.1177/1129729818762977. Epub 2018 Mar 26.
: Centers for Medicare and Medicaid Services have determined that chronic dialysis units should have <12% of their patients utilizing central venous catheters for hemodialysis treatments. On the Eastern Shore of Maryland, the central venous catheter rates in the dialysis units averaged >45%. A multidisciplinary program was established with goals of decreasing catheter rates in order to decrease central line-associated bloodstream infections, decrease mortality associated with central line-associated bloodstream infection, decrease hospital days, and provide savings to the healthcare system.
: We collected the catheter rates within three dialysis centers served over a 5-year period. Using published data surrounding the incidence and related costs of central line-associated bloodstream infection and mortality per catheter day, the number of central line-associated bloodstream infection events, the costs, and the related mortality could be determined prior to and after the initiation of the dialysis access program.
: An organized dialysis access program resulted in a 82% decrease in the number of central venous catheter days which lead to a concurrent reduction in central line-associated bloodstream infection and deaths. As a result of creating an access program, central venous catheter rates decreased from an average rate of 45% to 8%. The cost savings related to the program was calculated to be over US$5 million. The decrease in the number of mortalities is estimated to be between 13 and 27 patients.
: We conclude that a formalized access program decreases catheter rates, central line-associated bloodstream infection, and the resultant hospitalizations, mortality, and costs. Areas with high hemodialysis catheter rates should develop access programs to better serve their patient population.
医疗保险和医疗补助服务中心已确定,慢性透析单位接受血液透析治疗时使用中心静脉导管的患者比例应低于12%。在马里兰州东海岸,透析单位的中心静脉导管使用率平均超过45%。于是设立了一个多学科项目,目标是降低导管使用率,以减少中心静脉导管相关血流感染、降低与中心静脉导管相关血流感染相关的死亡率、减少住院天数,并为医疗系统节省开支。
我们收集了在5年期间服务的三个透析中心内的导管使用率。利用已发表的关于中心静脉导管相关血流感染的发生率、相关成本以及每导管日死亡率的数据,可以在透析通路项目启动之前和之后确定中心静脉导管相关血流感染事件的数量、成本和相关死亡率。
一个有组织的透析通路项目使中心静脉导管使用天数减少了82%,这同时导致中心静脉导管相关血流感染和死亡人数减少。由于创建了一个通路项目,中心静脉导管使用率从平均45%降至8%。该项目节省的成本计算超过500万美元。死亡率的下降估计在13至27名患者之间。
我们得出结论,一个正规化的通路项目可降低导管使用率、中心静脉导管相关血流感染以及由此导致的住院率、死亡率和成本。血液透析导管使用率高的地区应制定通路项目,以更好地服务其患者群体。